CA2901162C - Purification of rapamycin derivatives - Google Patents

Purification of rapamycin derivatives Download PDF

Info

Publication number
CA2901162C
CA2901162C CA2901162A CA2901162A CA2901162C CA 2901162 C CA2901162 C CA 2901162C CA 2901162 A CA2901162 A CA 2901162A CA 2901162 A CA2901162 A CA 2901162A CA 2901162 C CA2901162 C CA 2901162C
Authority
CA
Canada
Prior art keywords
purification
rapamycin derivatives
biolimus
formula
purified
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2901162A
Other languages
English (en)
French (fr)
Other versions
CA2901162A1 (en
Inventor
Margaret W. KAYO
Richard S. Fornicola
Ivan KOVACIK
Leelakrishna Kondaveti
Aniruddh SINGH
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biosensors International Group Ltd
Original Assignee
Biosensors International Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biosensors International Group Ltd filed Critical Biosensors International Group Ltd
Publication of CA2901162A1 publication Critical patent/CA2901162A1/en
Application granted granted Critical
Publication of CA2901162C publication Critical patent/CA2901162C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18Bridged systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2901162A 2013-03-15 2014-03-17 Purification of rapamycin derivatives Active CA2901162C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361799857P 2013-03-15 2013-03-15
US61/799,857 2013-03-15
PCT/US2014/030602 WO2014145780A1 (en) 2013-03-15 2014-03-17 Purification of rapamycin derivatives

Publications (2)

Publication Number Publication Date
CA2901162A1 CA2901162A1 (en) 2014-09-18
CA2901162C true CA2901162C (en) 2021-06-01

Family

ID=51538094

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2901162A Active CA2901162C (en) 2013-03-15 2014-03-17 Purification of rapamycin derivatives

Country Status (8)

Country Link
US (5) US9598439B2 (OSRAM)
EP (1) EP2972258B1 (OSRAM)
JP (4) JP2016519086A (OSRAM)
CN (2) CN108864149B (OSRAM)
CA (1) CA2901162C (OSRAM)
ES (1) ES2897473T3 (OSRAM)
SG (3) SG10202112135VA (OSRAM)
WO (1) WO2014145780A1 (OSRAM)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2934401C (en) 2009-11-02 2017-01-10 Pulse Therapeutics, Inc. Magnetomotive stator system and methods for wireless control of magnetic rotors
SG10202112135VA (en) 2013-03-15 2021-12-30 Biosensors International Group Ltd Purification of rapamycin derivatives
CN109851626B (zh) * 2019-01-08 2021-11-02 扬子江药业集团四川海蓉药业有限公司 一种替西罗莫司的分离纯化方法
CN116102576B (zh) * 2021-11-09 2025-08-29 上海博畅医疗科技有限公司 一种优美莫司晶体的制造方法及其应用

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9713730D0 (en) * 1997-06-30 1997-09-03 Ciba Geigy Ag Organic compounds
US20060198867A1 (en) * 1997-09-25 2006-09-07 Abbott Laboratories, Inc. Compositions and methods of administering rapamycin analogs using medical devices for long-term efficacy
US7452692B2 (en) 2002-02-13 2008-11-18 Teva Gyógyszergyár Zártkörüen Müködö Részvénytársaság Method for extracting a macrolide from biomatter
KR20050114262A (ko) * 2003-03-31 2005-12-05 테바 기오기스제르갸르 레스즈베니타르사사그 마크로라이드의 결정화 및 정제
US7220755B2 (en) * 2003-11-12 2007-05-22 Biosensors International Group, Ltd. 42-O-alkoxyalkyl rapamycin derivatives and compositions comprising same
WO2005054253A1 (en) * 2003-12-05 2005-06-16 Biocon Limited Process for the purification of macrolides
JP4716280B2 (ja) * 2004-03-01 2011-07-06 テルモ株式会社 O−アルキル化ラパマイシン誘導体の製造法
JP4224115B2 (ja) * 2004-04-14 2009-02-12 ワイス ラパマイシン42−エステル誘導体の位置特異的合成
TW200628483A (en) 2004-12-01 2006-08-16 Teva Gyogyszergyar Zartkoruen Mukodo Reszvenytarsasag Processes for producing crystalline macrolides
RU2007130406A (ru) * 2005-03-02 2009-04-10 Вайет (Us) Очистка рапамицина
US20060222627A1 (en) * 2005-03-30 2006-10-05 Andrew Carter Optimizing pharmacodynamics of therapeutic agents for treating vascular tissue
AR058283A1 (es) * 2005-12-07 2008-01-30 Wyeth Corp Metodos para la preparacion de rapamicina cristalina y para la medicion de la cristalinidad de los compuestos de rapamicina utilizando calorimetria diferencial de barrido
US7700614B2 (en) * 2005-12-14 2010-04-20 Abbott Laboratories One pot synthesis of tetrazole derivatives of rapamycin
GB0601406D0 (en) * 2006-01-24 2006-03-08 Novartis Ag Organic Compounds
US7605257B2 (en) 2006-03-07 2009-10-20 Wyeth Processes for preparing water-soluble polyethylene glycol conjugates of macrolide immunosuppressants
US7812032B2 (en) * 2006-07-25 2010-10-12 Abbott Laboratories Crystalline forms of rapamycin analogs
US7820812B2 (en) * 2006-07-25 2010-10-26 Abbott Laboratories Methods of manufacturing crystalline forms of rapamycin analogs
WO2008056372A1 (en) * 2006-11-10 2008-05-15 Biocon Limited A pure form of rapamycin and a process for recovery and purification thereof
WO2008065887A1 (en) * 2006-11-27 2008-06-05 Terumo Kabushiki Kaisha Process for producing o-alkylated rapamycin derivative, and o-alkylated rapamycin derivative
US20080287675A1 (en) * 2007-05-18 2008-11-20 Abbott Laboratories Cascade system
CN101077334A (zh) * 2007-06-29 2007-11-28 济南康泉医药科技有限公司 含酪氨酸激酶抑制剂的抗癌组合物
TW200948361A (en) 2008-05-26 2009-12-01 Chunghwa Chemical Synthesis & Biotech Co Ltd Method for synthesizing Biolimus A9 and the like and method for improving stability of the same
US20100055145A1 (en) * 2008-08-29 2010-03-04 Biosensors International Group Stent coatings for reducing late stent thrombosis
WO2010124098A2 (en) 2009-04-24 2010-10-28 Boston Scientific Scimed, Inc. Use of drug polymorphs to achieve controlled drug delivery from a coated medical device
CN102464669B (zh) * 2010-11-17 2014-04-16 浙江海正药业股份有限公司 无定形依维莫司及其制备方法
US8669360B2 (en) * 2011-08-05 2014-03-11 Boston Scientific Scimed, Inc. Methods of converting amorphous drug substance into crystalline form
US9056152B2 (en) * 2011-08-25 2015-06-16 Boston Scientific Scimed, Inc. Medical device with crystalline drug coating
CN102786534A (zh) * 2012-05-25 2012-11-21 上海现代制药股份有限公司 一种依维莫司的制备方法
SG10202112135VA (en) 2013-03-15 2021-12-30 Biosensors International Group Ltd Purification of rapamycin derivatives

Also Published As

Publication number Publication date
US20170334928A1 (en) 2017-11-23
CN105102967A (zh) 2015-11-25
US11780850B2 (en) 2023-10-10
WO2014145780A4 (en) 2014-11-20
CN105102967B (zh) 2018-10-12
EP2972258A1 (en) 2016-01-20
US20220024947A1 (en) 2022-01-27
JP2016519086A (ja) 2016-06-30
JP2019089848A (ja) 2019-06-13
HK1218959A1 (zh) 2017-03-17
WO2014145780A1 (en) 2014-09-18
US20190256527A1 (en) 2019-08-22
SG10202112135VA (en) 2021-12-30
CA2901162A1 (en) 2014-09-18
SG11201507406YA (en) 2015-10-29
JP2021121601A (ja) 2021-08-26
US20200270272A1 (en) 2020-08-27
CN108864149B (zh) 2022-04-05
US20160002262A1 (en) 2016-01-07
US10597406B2 (en) 2020-03-24
EP2972258A4 (en) 2016-12-21
ES2897473T3 (es) 2022-03-01
SG10201707632PA (en) 2017-11-29
US9598439B2 (en) 2017-03-21
US10202402B2 (en) 2019-02-12
CN108864149A (zh) 2018-11-23
JP2023164476A (ja) 2023-11-10
US11046711B2 (en) 2021-06-29
EP2972258B1 (en) 2021-08-04

Similar Documents

Publication Publication Date Title
PH12015500263A1 (en) New bicyclic derivatives
PH12014501179B1 (en) New bicyclic dihydroisoquinoline-1-one derivatives
PH12015501934A1 (en) New octahydro - pyrrolo [3,4-c] - pyrrole derivatives and analogs thereof as autotaxin inhibitors
MY199066A (en) Processes for producing diazabicyclooctane compounds
MY169043A (en) New dihydroquinoline-2-one derivatives
MX2016011992A (es) Derivados de piperidina-diona.
MX2014014531A (es) Derivados de aminoquinazolina y piridopirimidina.
PH12015501363A1 (en) Chloro-pyrazine carboxamide derivatives with epithelial sodium channel blocking activity
MX341456B (es) Amino-quinolinas como inhibidores de cinasa.
MX2015011436A (es) Triazolopiridinas sustituidas y metodos para usarlas.
PH12014500814A1 (en) New aryl-quinoline derivatives
MX2015017156A (es) Inhibidores de bace.
AU2014230812A8 (en) Process for making benzoxazepin compounds
MX353190B (es) Derivados de isoquinolina y naftiridina.
JO3063B1 (ar) مركب مبتكر وطرق لانتاجه
AU2012342891A8 (en) 3-Cyanoaryl-1H-pyrrolo[2.3-b]pyridine derivatives
MA40250A (fr) Dérivés de quinolizinone utilisés comme inhibiteurs de pi3k
MX2015013224A (es) Inhibidores macrociclicos y biciclicos del virus de la hepatitis c.
JOP20200030A1 (ar) مركب خماسي الحلقة
CA2901162C (en) Purification of rapamycin derivatives
PH12017501404A1 (en) Diaza-benzofluoranthrene compounds
MX2016006807A (es) Derivados de imidazol.
IN2013MU03704A (OSRAM)
TN2017000065A1 (en) A tetrahydropyrrolo[3,4-d][1,3]thiazine-derivative as bace inhibitor
MX2016005511A (es) Intermediarios y metodos para sintetizar derivados de calicheamicina.

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20190306